Clinical Trials

Inclusion Criteria:

- Age ≥ 18 years up to ≤ 75 years at the time of informed consent

- Confirmed diagnosis of melanoma, non-small cell lung cancer (NSCLC), or colorectal
cancer (CRC) that is metastatic or locally advanced or unresectable and is relapsed
and/or refractory (R/R) after standard therapy for each tumor histology

- Participants must have received prior systemic treatment for their metastatic disease
or locally advanced disease based on tumor type as follows:

- Melanoma: participants with disease progression following an immune checkpoint
inhibitor (CPI) and if BRAF-mutated, BRAF/MEK inhibition

- NSCLC: participants with disease progression following at least 1 approved systemic
therapy, including an immune CPI-containing regimen for appropriate patients or an
approved targeted therapy for known molecular abnormalities if applicable to their
disease

- CRC: participants with disease progression following at least 1 line of therapy,
including a fluoropyrimidine with oxaliplatin or irinotecan. Microsatellite
instability (MSI) high/mismatch repair deficient (dMMR) CRC participants must have
disease progression following systemic therapy with immune CPIs.

- Measurable disease including at least 1 lesion that is safely resectable AND a target
lesion to measure response and an additional lesion for biopsy

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Adequate organ and marrow function

- Women of childbearing potential must have a negative pregnancy test at screening

- All participants must agree to practice highly effective methods of contraception

Exclusion Criteria:

- Prior treatment with adoptive cellular therapy

- Prior solid organ transplantation

- Central nervous system (CNS) involvement of disease that is extensive, symptomatic or
untreated, or patients with leptomeningeal disease

- Uncontrolled or symptomatic pleural effusion or ascites

- Untreated or active systemic infection

- Active autoimmune disease requiring treatment or primary immunodeficiency syndrome

- Systemic corticosteroids at a dose of >10 mg of prednisone or equivalent per day

- Other primary malignancy within 3 years prior to enrollment

- Impaired cardiac function or clinically significant cardiovascular disease

- Required chronic anticoagulation, such as warfarin, low molecular weight heparin, or
Factor Xa inhibitors

- Pregnant or nursing (lactating) women

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 10/30/23. Questions regarding updates should be directed to the study team contact.